PayerTalkCE™ Presents: Advancing Equity: Pediatric Atopic Dermatitis Management in Managed Care

Release Date: November 1, 2024
Expiration Date: May 1, 2026
Estimated Time to Complete Activity: 0.5 hours
Compatible with all modern browsers and mobile devices

Expert Faculty Presenters:


	Gary M. Owens, MD President Gary Owens Associates, Inc. Click here for biography

	Joy Wan, MD, MSCE Assistant Professor of Dermatology John Hopkins University School of Medicine Click here for biography

Target Audience
The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations. Other managed care professionals include nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.

Statement of Need/Program Overview
This program provides an understanding of the overall burden of atopic dermatitis (AD) in children and recommended treatments that can empower managed care, specialty pharmacy, and other payer decision makers to implement health care benefit policy strategies that will enhance optimal treatment outcomes.

Educational Objectives
After completing this activity, the participant should be better able to:

Examine the experiences of pediatric patients and their caregivers in managing moderate-to-severe AD
Outline evidence-based treatment recommendations in pediatric AD
Explore collaborative strategies for the implementation of equitable drug coverage policies for pediatric AD treatments

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE), the National Eczema Association (NEA) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
PACE designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-24-251-H01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Disclosures
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

*Name of Faculty*	*Reported Financial Relationship*
Gary M. Owens, MD	Consultant/Advisor/Speaker: Sanofi, Regeneron, Incyte, Baxter, CyRx, BD, Sage Therapeutics.
Joy Wan, MD, MSCE	Consultant/Advisor/Speaker: Janssen Researcher: Pfizer Data Monitoring Committee Member: Sun Pharmaceuticals

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.